Recent News

• 11.02.2026 - Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
• 10.29.2026 - Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
• 10.20.2026 - Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
• 10.19.2026 - Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
• 09.11.2026 - Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
• 08.12.2026 - Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• 11.12.2024 - Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
• 07.23.2024 - July 2024 Investor Presentation
• 07.23.2024 - July 2024 Investor Presentation
• 07.11.2024 - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Recent Filings

• 10.22.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 10.22.2026 - 8-K Current report
• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 3 Initial statement of beneficial ownership of securities
• 09.18.2026 - EFFECT Notice of Effectiveness
• 09.11.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.11.2026 - 8-K Current report
• 08.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]